Skip to main content
. 2023 May 19;11(5):e006714. doi: 10.1136/jitc-2023-006714

Figure 1.

Figure 1

Anti-PD-L1-mAb does not stimulate sufficient DC3 and T-cell activation in MC38 tumors. (A) Diagram of MC38 tumor-bearing mice receiving anti-PD-L1-mAb. (B) Average tumor growth (left) and Kaplan-Meier survival curve (right) of MC38 tumor-bearing mice treated with anti-PD-L1-mAb or control (n=8 mice/condition). The number of tumor-free mice is indicated in brackets. (C and D) Flow cytometry analysis of MC38 tumors after 4 days of treatment showing proportions of total DCs (C) and DC subsets (D) (n=5 mice/condition). (E) Flow cytometry analysis of IL-12 and CD80 expression (mean fluorescence intensity, MFI) in DC subsets in MC38 tumors 4 days after treatment (n=5 mice/condition). Data are presented as mean±SEM. For comparisons between multiple groups and variables, two-way analysis of variance was used. For survival analysis, the Mantel-Cox log-rank was used. For comparisons between two groups, Student’s two-tailed t-test was used. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. cDC, conventional DC; DC, dendritic cell; IL, interleukin; mAb, monoclonal antibody; MHC, major histocompatibility complex; PD-L1, programmed cell death ligand 1; s.c., subcutaneously.